WOF releases position statement addressing weight stigma and changing obesity narratives
The World Obesity Federation has released position statement addressing weight stigma and changing obesity narratives. The statement,...
top of page
Browse by category
Search
GLP-1/GIP candidate VK2735 shows reductions in subjects' liver fat content and plasma lipid levels
Outcomes from Viking Therapeutics’ Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were...
Gelesis’ hydrogel promotes weight loss and metabolic health by targeting the gut-liver axis
Weight loss resulting from Gelesis’ superabsorbent hydrogel treatment is not only a result of its space-occupying properties, the...
Significant association between eating disorders and physical multimorbidity
A UK study has revealed a significant association between eating disorders and physical multimorbidity, revealing new information on the...
Revisional LSG after LAGB achieves long-term weight loss but higher peri-operative complications
Revisional laparoscopic sleeve gastrectomy provides long-term weight loss, although peri-operative complications are significantly...
Single-port LSG is viable alternative to multiport LSG
Single-port laparoscopic sleeve gastrectomy (SILSG) is a viable alternative procedure to multiport conventional sleeve gastrectomy (CLSG)...
FDA clears GE HealthCare’s Allia IGS Pulse next generation of image-guided systems
GE HealthCare has gained FDA 510(k) clearance of the Allia IGS Pulse - the latest addition to the company’s image guided system (IGS)...
High-performance ultrasound probes improve imaging in patients with obesity
Obesity can impair ultrasound imaging quality of abdominal anatomy, specifically the liver and kidneys, and the application of...
SURMOUNT-3: Tirzepatide shows total mean weight loss of 26.6% from study entry over 84 weeks
Detailed results from the phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with...
Carmot’s CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetes
Carmot Therapeutics has revealed preliminary data from the single ascending dose (SAD) portion of its ongoing Phase 1 clinical trial for...
Browse by tag
bottom of page